Clinical Remissions In Three Otherwise Intractable Cancers Signal The Progress Of Targeted Genetic Medicine
Remarkably, a Catholic priest, who was previously bedridden and in withering pain, suffering from end-stage prostate cancer that had spread to his bones, received successive courses of Rexin-G, during which time the bone pain was relieved, the PSA tumor markers fell, the bone tumors stopped growing, and even the previously inoperable primary tumor disappeared on follow-up CT scans. As the priest's bones began to heal and strengthen, he arose from his bed and is currently saying daily Mass and delivering lectures in the seminary. What is even more remarkable is that this revered man of the cloth was over ninety years old at the time of his treatment and remission. This past week, the latest good news comes from the trenches of Stage IVb pancreas cancer, where a complete clinical remission was documented in a patient undergoing Rexin-G treatment as stand-alone therapy in an ongoing U.S. Phase I/II clinical trial.
According to Erlinda Maria Gordon, M.D., Medical Director of Epeius Biotech, "It is gratifying to learn that more and more eminent medical oncologists around the world are recommending Rexin-G as 'Best Care' for patients with refractory metastatic disease, and even more gratifying to show how truly effective Rexin-G at these doses can be in eradicating such difficult cancers." Indeed, as the unprecedented single-agent efficacy of Rexin-G is incontrovertibly demonstrated in an increasing number of chemo-resistant cancers, the progressive steps of these intrepid pioneers may provide a rational basis of hope and expectation for many when standard therapy has failed. Rexin-G is approved for the treatment of all solid tumors in the Philippines, and has been granted both Orphan Drug Status for pancreas cancer, osteosarcoma and soft tissue sarcoma, and Fast Track Designation for pancreas cancer by the U.S. FDA.
About Epeius Biotechnologies
Epeius Biotechnologies Corporation is a privately held biopharmaceutical company dedicated to the advancement of genetic medicine with the development and commercialization of its proprietary targeted delivery systems.
Source: Epeius Biotechnologies Corporation
There are no references listed for this article.
Please use one of the following formats to cite this article in your essay, paper or report:
Corporation, Epeius Biotechnologies. "Clinical Remissions In Three Otherwise Intractable Cancers Signal The Progress Of Targeted Genetic Medicine." Medical News Today. MediLexicon, Intl., 13 Oct. 2009. Web.
25 May. 2016. <http://www.medicalnewstoday.com/releases/167087.php>
Corporation, E. (2009, October 13). "Clinical Remissions In Three Otherwise Intractable Cancers Signal The Progress Of Targeted Genetic Medicine." Medical News Today. Retrieved from
Please note: If no author information is provided, the source is cited instead.
Contact our news editors
For any corrections of factual information, or to contact our editorial team, please see our contact page.
Copyright Medical News Today: Excluding email/sharing services explicitly offered on this website, material published on Medical News Today may not be reproduced, or distributed without the prior written permission of Medilexicon International Ltd. Please contact us for further details.